0.69
-9.87%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Transcenta Holding
Its shares trade on HKEX under the ticker 6628.HK. It has been listed since 29 September 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥7.2m and a net loss of CN¥198.5m. At that date it held total assets of CN¥925.2m and shareholders' equity of CN¥618.4m.
Transcenta Holding Ltd. is a clinical stage global biopharmaceutical company, which engages in discovery, research, development, and manufacturing of differentiated antibody therapies in therapeutic areas with high unmet medical needs. The company is headquartered in Suzhou, Anhui. The company went IPO on 2021-09-29. The firm's products include MSB2311, TST001, TST005, TST002, TST004, TST003, TST008, MSB0254 and TST006. The firm's all products are in the research and development (R&D) stage and have not been commercialized. The firm also provides contract developmentand manufacturing organization (CDMO) services, mainly including process development services, GMP / cGMP production services, cell line development services, sample testing services, formula optimization services and drug formation research.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Sept 2021
- Employees
- 318
- Website
- transcenta.com ↗
Leadership
Pay as last reported
- Dr. Xueming QianExecutive Chairman of the Board, Chief Executive OfficerCN¥5.2m
- Mr. Weng XiaoluChief Financial Officer, since 2021
- Dr. Feng YeChief Operating Officer, Executive Vice President
- Dr. Christopher HwangExecutive Vice President, Chief Technology Officer
- Dr. Xiaoming YangExecutive Vice President - Global Process and Product Development, General Manager of CDMO
- Dr. Yi GuSenior Vice President and Head of Research
- Ms. Jane Qin XiaVice President of Commercial Planning and Business Development
- Ms. Wei WangSecretary to the Board
- Dr. Xu LiNon-Executive Director
- Ms. Wei ChenNon-Executive Independent Director
- Dr. Kumar SrinivasanNon-Executive Independent Director
- Mr. Jiasong TangNon-Executive Independent DirectorCN¥50,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Clinical stage global biopharmaceutical company with 318 employees in Suzhou, China.
- Developing differentiated antibody therapies for high unmet medical needs in therapeutic areas.
- Offering CDMO services including process development and GMP production services.
Weaknesses
- All products are in R&D stage with no commercialized therapies yet.
- No commercialized products mean no revenue from product sales currently.
- R&D stage products face high development and regulatory risks.
Opportunities
- Expanding CDMO services to support global biopharmaceutical clients.
- Growing demand for antibody therapies in high unmet medical need areas.
- Potential for product commercialization after successful R&D completion.
Threats
- Regulatory hurdles for new biopharmaceutical products in global markets.
- Competition from established biotech firms in antibody therapy development.
- High costs associated with R&D and manufacturing of biopharmaceuticals.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.